| 2/7/2020 | CV | Market Commentary: Morning Commentary: Smart Global convertible notes expand on debut; Assertio in focus
|
| 8/29/2018 | CV | Market Commentary: Convertibles trading light; ServiceNow, Unisys reach new heights; Depomed notes active
|
| 7/31/2018 | BKCACV | S&P downgrades Depomed
|
| 7/10/2018 | CV | Market Commentary: Sempra on tap; Palo Alto’s $1.5 billion deal hits the market; Depomed up on the week
|
| 12/14/2017 | BKCACV | S&P changes Depomed view
|
| 12/6/2017 | CV | Market Commentary: Granite Point talks new deal; Cleveland-Cliffs tops par; pharmaceutical names eyed
|
| 12/5/2017 | CV | Market Commentary: Market awaits Cleveland Cliffs issue, Depomed on the rise, General Cable in demand
|
| 10/26/2017 | CV | Market Commentary: Weibo jumps; China Lodging on tap; Depomed eyed as Trump takes aim at ‘opioid crisis’
|
| 10/17/2017 | CV | Market Commentary: Impax Laboratories jumps in active trade after merger news; Herbalife slips; Cemex up
|
| 8/8/2017 | DD | Market Commentary: Valeant results beat, bonds firm; Endo earnings better, but forecasts lowered; Depomed convertibles tank
|
| 8/8/2017 | HY | Market Commentary: Valeant results beat, bonds firm; Endo earnings better; Depomed convertibles tank
|
| 8/8/2017 | CV | Market Commentary: BioMarin paper wanes in wake of new issue; Blackstone dips on add-on; Depomed tanks
|
| 8/7/2017 | BK | Depomed withdraws $350 million term loan B from market
|
| 7/13/2017 | BKCACV | S&P rates Depomed loan BB-, convertibles B-
|
| 7/12/2017 | BK | Market Commentary: DexKo final terms surface; Diversey, U.S. Security, ASG Technologies, Cypress set price talk
|
| 7/12/2017 | CLHY | Market Commentary: DexKo final terms set; Diversey, U.S. Security, ASG Technologies, Cypress set price talk
|
| 7/12/2017 | BK | Depomed readies launch of $350 million term loan B for Thursday
|
| 5/10/2017 | CV | Market Commentary: Depomed convertible notes recover from day’s lows; Vitamin Shoppe loses ground
|
| 5/10/2017 | CV | Market Commentary: Morning Commentary: Depomed convertibles weaken on wider loss; Dermira, Becton deals on deck
|
| 4/4/2017 | CV | Market Commentary: Acorda convertibles under pressure; Depomed edges up on debt payment; Gogo goes up
|
| 4/4/2017 | LMPV | Depomed prepays $100 million more loans with Deerfield, Pharmakon
|
| 4/4/2017 | CV | Market Commentary: Morning Commentary: Acorda Therapeutics convertibles under pressure; Depomed edges up on payment
|
| 2/22/2017 | CV | Market Commentary: Parker Drilling’s new preferreds fizzle; fresh earnings drive movement in DISH, Tesla
|
| 11/8/2016 | CV | Market Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed; Iconix steady
|
| 11/8/2016 | CV | Market Commentary: Morning Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed
|
| 11/3/2016 | CV | Market Commentary: Depomed convertible bonds lose ground amid takeover talk; election eyed; Dynegy recovers
|
| 11/3/2016 | CV | Market Commentary: Morning Commentary: Depomed convertible bonds lose ground amid takeover talk; election still eyed
|
| 10/4/2016 | CV | Market Commentary: Depomed on radar in wake of patent suit win; NXP still active; NQ Mobile settles placement
|
| 10/4/2016 | CV | Market Commentary: Morning Commentary: Depomed remains on radar; NXP notes still active; NQ Mobile settles placement
|
| 10/3/2016 | CV | Market Commentary: Ship Finance new issue steady; Depomed better on patent suit win; Tesla convertibles firm
|
| 10/3/2016 | CV | Market Commentary: Morning Commentary: Ship Finance new issue steady; Depomed busy on patent suit win; Tesla rises
|
| 9/19/2016 | CV | Market Commentary: Morning Commentary: DepoMed’s convertibles trade just under 140; PTC Therapeutics poised to move up
|
| 5/9/2016 | PP | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
| 5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
| 4/13/2016 | PP | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
| 4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
| 4/12/2016 | PP | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
| 4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
| 4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
| 4/8/2016 | PP | Market Commentary: Depomed surges after activist letter to the board; Yahoo! richens on deal chatter
|
| 4/8/2016 | CV | Market Commentary: Depomed surges after activist letter to the board; Yahoo! richens on deal chatter
|
| 4/8/2016 | CV | Market Commentary: Morning Commentary: Depomed surges in active trade after activist letter to the board
|
| 4/7/2016 | PP | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 4/4/2016 | LMPV | Depomed prepays $100 million of facility with Deerfield, Pharmakon
|
| 3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
| 1/11/2016 | PP | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
| 1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
| 1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
| 10/24/2015 | DD | Market Commentary: Valeant leads pharma rebound; Platform Specialty off as CEO plans exit; energy names slide
|
| 10/23/2015 | PP | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
| 10/23/2015 | CV | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
| 9/22/2015 | PP | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
| 9/22/2015 | CV | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
| 7/20/2015 | PP | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
| 7/20/2015 | CV | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
| 7/7/2015 | PP | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
| 7/7/2015 | CV | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
| 7/7/2015 | CV | Market Commentary: Morning Commentary: Medicines convertibles higher in active trade; Depomed deflects Horizon offer
|
| 5/12/2015 | PP | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
| 5/12/2015 | CV | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
| 5/12/2015 | CV | Market Commentary: Morning Commentary: Planned SunEdison looks cheap; existing SunEdisons in focus; Depomed lower
|
| 4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
| 3/13/2015 | PP | Market Commentary: FXCM bumps up on positive earnings; Herbalife adds outright, unchanged dollar neutral
|
| 3/13/2015 | CV | Market Commentary: FXCM bumps up on positive earnings; Herbalife adds outright, unchanged dollar neutral
|
| 3/12/2015 | PV | New Issue: Depomed to issue $575 million of seven-year notes to Deerfield
|
| 2/24/2015 | CV | Market Commentary: Morning Commentary: American Tower on tap with $1.25 billion mandatory; secondary softens
|
| 9/9/2014 | CV | Market Commentary: Convertibles mixed to weaker; Yahoo! lower outright, on hedge; Molina mixed; Herbalife up
|
| 9/9/2014 | CV | Depomed greenshoe exercise lifts convertible sale to $345 million
|
| 9/9/2014 | CV | Market Commentary: Morning Commentary: Yahoo convertibles move lower outright, on hedge; Depomed adds
|
| 9/5/2014 | PP | Market Commentary: New Huron Consulting trades at par; Depomed shares push higher after court decision
|
| 9/5/2014 | CV | Market Commentary: New Huron Consulting trades at par; Depomed shares push higher after court decision
|
| 9/5/2014 | CV | Market Commentary: Morning Commentary: New Huron trades around issue price; Depomed slips with shares
|
| 9/4/2014 | PP | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
| 9/4/2014 | CV | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
| 9/4/2014 | CV | Market Commentary: Morning Commentary: Clovis, Depomed add with underlying shares mixed; Electronics For Imaging gains
|
| 9/4/2014 | CV | New Issue: Depomed sells upsized $300 million seven-year convertibles to yield 2.5%, up 37%
|
| 9/3/2014 | PP | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
| 9/3/2014 | CV | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
| 9/3/2014 | CV | Market Commentary: Morning Commentary: New deals in focus; Clovis Oncology shares sharply lower; Exelixis slips
|
| 9/2/2014 | PP | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
| 9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
| 9/2/2014 | CV | Depomed plans $230 million seven-year convertibles to yield 2.625%-3.125%, up 30%-35%
|
| 5/25/2012 | CVHYPF | Depomed files $100 million shelf covering stock, debt and preferreds
|
| 12/31/2008 | CVHY | Depomed files $100 million shelf registration
|
| 9/19/2008 | SS | Biovail Laboratories sells 841,885 shares of DepoMed
|
| 4/24/2007 | PP | Market Commentary: Halozyme secures $32.09 million from private placement; Adaltis plans C$28 million stock offering
|
| 4/23/2007 | PP | Market Commentary: Depomed seals $20 million direct placement of stock; Arbios raises $4.8 million
|
| 4/23/2007 | PP | New Issue: Depomed closes $20 million direct placement
|
| 12/12/2006 | PP | New Issue: Depomed receives $30 million equity line
|
| 12/12/2006 | PP | Market Commentary: Depomed seals $30 million equity line; HemoSense wraps $6.99 million stock sale
|
| 9/21/2006 | BT | Depomed, King Pharmaceuticals considering agreement for Glumetza combination product
|
| 9/21/2006 | BT | Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
|
| 8/23/2006 | BT | Depomed, King Pharmaceuticals to launch Glumetza as new ADA guidelines are issued
|
| 8/23/2006 | BT | Market Commentary: Cell Therapeutics' stock takes off on positive phase 1 data; Cubist's stock up again on Theravance news
|
| 8/15/2006 | BT | Depomed's reflux disease compound shows improved absorption in phase 1 trial
|
| 8/7/2006 | BT | Depomed signs agreement with Patheon, says Esprit planning to make $10 million payment in December
|
| 7/24/2006 | BT | Depomed amends marketing, payment agreement with Esprit Pharma
|
| 7/24/2006 | BT | Market Commentary: Genitope falls 12%; Micromet off; Oscient up; DepoMed dives; Atricure off; Discovery Labs rises 10%
|
| 7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
| 6/28/2006 | BT | Market Commentary: Replidyne debut shaky but closes in the green; Indevus rises in face of spot sale; Depomed loses 3%
|
| 6/28/2006 | BT | King Pharmaceuticals, Depomed to co-promote Glumetza for type 2 diabetes
|
| 6/26/2006 | BT | Depomed: open label studies support development of Gabapentin GR in postherpetic neuralgia
|
| 6/7/2006 | BT | Depomed trial shows Glumetza plus sulfonylurea treatment effective in glycemic control in type 2 diabetes
|
| 5/10/2006 | BT | Depomed finalizes phase 3 clinical trial protocol for Gabapentin GR
|
| 4/11/2006 | BT | Depomed extended-release Glumetza controls glucose levels effectively, study says
|
| 3/29/2006 | BT | Depomed, Madaus announce Swedish approval of ProQuin XR for urinary tract infections
|
| 3/14/2006 | BT | Depomed says 2005 revenue zooms on heels of Boehringer collaboration, product launches
|
| 1/11/2006 | BT | Depomed files suit alleging IVAX infringed on two AcuForm patents
|
| 1/4/2006 | BT | Depomed: Research shows Gabapentin GR significantly reduces pain for neuralgia patients
|
| 1/4/2006 | BT | Market Commentary: Kosan deal revival speculated; SGX range for IPO emerges; Depomed zooms; PDLI up 5%
|
| 12/20/2005 | BTCV | Depomed files $100 million shelf
|
| 12/13/2005 | BT | Depomed withdraws lawsuit against Biovail as companies revise Glumetza agreement
|
| 11/29/2005 | BT | Depomed, Madaus enter distribution and supply agreement for ProQuin XR
|
| 11/23/2005 | BT | Depomed, Biovail agree to temporary standstill on Glumetza lawsuit
|
| 10/24/2005 | BT | Depomed completes enrollment for Gabapentin phase II trial
|
| 1/7/2005 | PP | New Issue: Depomed plans direct placement of stock for $22.7 million
|
| 1/7/2005 | PP | Market Commentary: Private placement volume improves slightly; Depomed plans $22.7 million offering
|
| 12/14/2004 | PP | Depomed, Kings Road resolve dispute over series A preferreds
|
